Asset Details
Do you wish to reserve the book?
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
Do you wish to request the book?
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
2020
Overview
Background
Gram-negative bacteria mediated gemcitabine resistance in pre-clinical models. We determined if intratumoural lipopolysaccharide (LPS) detection by immunohistochemistry is associated with outcome in advanced pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine and non-gemcitabine containing 1st-line chemotherapy.
Methods
We examined LPS on tumour tissue from 130 patients treated within the randomised AIO-PK0104 trial and a validation cohort (
n
= 113) and analysed the association of LPS detection to patient outcome according to treatment subgroups.
Results
In 24% of samples from the AIO-PK0104 study LPS was detected; in LPS-positive patients median OS was 4.4 months, compared to 7.3 months with LPS negative tumours (HR 1.732,
p
= 0.010). A difference in OS was detected in 1st-line gemcitabine-treated patients (
n
= 71; HR 2.377,
p
= 0.002), but not in the non-gemcitabine treatment subgroup (
n
= 59; HR 1.275,
p
= 0.478). Within the validation cohort, the LPS positivity rate was 23%, and LPS detection was correlated with impaired OS in the gemcitabine subgroup (
n
= 94; HR 1.993,
p
= 0.008) whereas no difference in OS was observed in the non-gemcitabine subgroup (
n
= 19; HR 2.596,
p
= 0.219).
Conclusions
The detection of intratumoural LPS as surrogate marker for gram-negative bacterial colonisation may serve as a negative predictor for gemcitabine efficacy in advanced PDAC.
Clinical trial registry
The Clinical trial registry identifier is NCT00440167.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adenocarcinoma - drug therapy
/ Aged
/ Biomarkers, Tumor - metabolism
/ Biomedical and Life Sciences
/ Clinical Trials, Phase III as Topic
/ Deoxycytidine - analogs & derivatives
/ Deoxycytidine - therapeutic use
/ Female
/ Humans
/ Lipopolysaccharides - metabolism
/ Male
/ Oncology
/ Pancreatic Neoplasms - diagnosis
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - mortality
/ Pancreatic Neoplasms - pathology
/ Patients
/ Randomized Controlled Trials as Topic
/ Translational Medical Research
/ Tumors
